- Home
- TXMD vs CVM Comparison
TXMD vs CVM Comparison
Compare TXMD & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TXMD
- CVM
- Stock Information
- Founded
- TXMD 2008
- CVM 1983
- Country
- TXMD United States
- CVM United States
- Employees
- TXMD N/A
- CVM N/A
- Industry
- TXMD Biotechnology: Pharmaceutical Preparations
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TXMD Health Care
- CVM Health Care
- Exchange
- TXMD Nasdaq
- CVM Nasdaq
- Market Cap
- TXMD 13.5M
- CVM 11.8M
- IPO Year
- TXMD N/A
- CVM 1987
- Fundamental
- Price
- TXMD $1.17
- CVM $3.46
- Analyst Decision
- TXMD
- CVM
- Analyst Count
- TXMD 0
- CVM 0
- Target Price
- TXMD N/A
- CVM N/A
- AVG Volume (30 Days)
- TXMD 35.2K
- CVM 1.6M
- Earning Date
- TXMD 08-11-2025
- CVM 08-14-2025
- Dividend Yield
- TXMD N/A
- CVM N/A
- EPS Growth
- TXMD N/A
- CVM N/A
- EPS
- TXMD N/A
- CVM N/A
- Revenue
- TXMD $1,841,000.00
- CVM N/A
- Revenue This Year
- TXMD $427.09
- CVM N/A
- Revenue Next Year
- TXMD N/A
- CVM N/A
- P/E Ratio
- TXMD N/A
- CVM N/A
- Revenue Growth
- TXMD 53.55
- CVM N/A
- 52 Week Low
- TXMD $0.70
- CVM $1.98
- 52 Week High
- TXMD $2.44
- CVM $66.60
- Technical
- Relative Strength Index (RSI)
- TXMD 47.76
- CVM 57.66
- Support Level
- TXMD $1.13
- CVM $2.24
- Resistance Level
- TXMD $1.24
- CVM $2.71
- Average True Range (ATR)
- TXMD 0.09
- CVM 0.51
- MACD
- TXMD 0.01
- CVM 0.25
- Stochastic Oscillator
- TXMD 73.12
- CVM 25.61
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.